|
1
|
Theodros D, Patel M, Ruzevick J, Lim M and
Bettegowda C: Pituitary adenomas: Historical perspective, surgical
management and future directions. CNS Oncol. 4:411–429. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 world health organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hirohata T, Ishii Y and Matsuno A:
Treatment of pituitary carcinomas and atypical pituitary adenomas:
A review. Neurol Med Chir (Tokyo). 54:966–973. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sinha S, Sharma BS and Mahapatra AK:
Microsurgical management of prolactinomas-clinical and hormonal
outcome in a series of 172 cases. Neurol India. 59:532–536. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Manuylova E, Calvi LM, Hastings C, Vates
GE, Johnson MD, Cave WT Jr and Shafiq I: Late presentation of
acromegaly in medically controlled prolactinoma patients.
Endocrinol Diabetes Metab Case Rep. 2016(pii): 16–0069.
2016.PubMed/NCBI
|
|
6
|
Ghadirian H, Shirani M, Ghazi-Mirsaeed S,
Mohebi S and Alimohamadi M: Pituitary apoplexy during treatment of
prolactinoma with cabergoline. Asian J Neurosurg. 13:93–95. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chng E and Dalan R: Pituitary apoplexy
associated with cabergoline therapy. J Clin Neurosci. 20:1637–1643.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nakhleh A, Shehadeh N, Hochberg I,
Zloczower M, Zolotov S, Taher R and Daoud Naccache D: Management of
cystic prolactinomas: A review. Pituitary. 21:425–430. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou W, Ma C and Yan Z: Microarray data
analysis reveals differentially expressed genes in prolactinoma.
Neoplasma. 62:53–60. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao L, Lin M and Wang S: Identification
of human prolactinoma related genes by DNA microarray. J Cancer Res
Ther. 10:544–548. 2014.PubMed/NCBI
|
|
11
|
Zhan X, Wang X and Cheng T: Human
pituitary adenoma proteomics: New progresses and perspectives.
Front Endocrinol (Lausanne). 7:542016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang W, Zang Z, Song Y, Yang H and Yin Q:
Co-expression network analysis of differentially expressed genes
associated with metastasis in prolactin pituitary tumors. Mol Med
Rep. 10:113–118. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Faraoni EY, Camilletti MA, Abeledo-Machado
A, Ratner LD, De Fino F, Huhtaniemi I, Rulli SB and Díaz-Torga G:
Sex differences in the development of prolactinoma in mice
overexpressing hCGβ: Role of TGFβ1. J Endocrinol. 232:535–546.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ko H, Kim JM, Kim SJ, Shim SH, Ha CH and
Chang HI: Induction of apoptosis by genipin inhibits cell
proliferation in AGS human gastric cancer cells via Egr1/p21
signaling pathway. Bioorg Med Chem Lett. 25:4191–4196. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu Z, Zhou Y, Cao Y, Dinh TL, Wan J and
Zhao M: Identification of candidate biomarkers and analysis of
prognostic values in ovarian cancer by integrated bioinformatics
analysis. Med Oncol. 33:1302016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Morris DG, Musat M, Czirják S, Hanzély Z,
Lillington DM, Korbonits M and Grossman AB: Differential gene
expression in pituitary adenomas by oligonucleotide array analysis.
Eur J Endocrinol. 153:143–151. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Michaelis KA, Knox AJ, Xu M,
Kiseljak-Vassiliades K, Edwards MG, Geraci M,
Kleinschmidt-DeMasters BK, Lillehei KO and Wierman ME:
Identification of growth arrest and DNA-damage-inducible gene beta
(GADD45beta) as a novel tumor suppressor in pituitary gonadotrope
tumors. Endocrinology. 152:3603–3613. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tong Y, Zheng Y, Zhou J, Oyesiku NM,
Koeffler HP and Melmed S: Genomic characterization of human and rat
prolactinomas. Endocrinology. 153:3679–3691. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Abdul Aziz NA, Mokhtar NM, Harun R, Mollah
MM, Mohamed Rose I, Sagap I, Mohd Tamil A, Wan Ngah WZ and Jamal R:
A 19-Gene expression signature as a predictor of survival in
colorectal cancer. BMC Med Genomics. 9:582016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang DW, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
Bioinformatics Resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Franken NA, Rodermond HM, Stao J, Haveman
J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc.
1:2315–2319. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cooper O, Mamelak A, Bannykh S, Carmichael
J, Bonert V, Lim S, Cook-Wiens G and Ben-Shlomo A: Prolactinoma
ErbB receptor expression and targeted therapy for aggressive
tumors. Endocrine. 46:318–327. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Castro-Ferreira R, Neves JS,
Ladeiras-Lopes R, Leite- Moreira AM, Neiva-Sousa M, Almeida-Coelho
J, Ferreira-Martins J and F Leite-Moreira A: Revisiting the slow
force response: The role of the PKG signaling pathway in the normal
and the ischemic heart. Rev Port Cardiol. 33:493–499. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hou J and Kang YJ: Regression of
pathological cardiac hypertrophy: Signaling pathways and
therapeutic targets. Pharmacol Ther. 135:337–354. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Babykutty S, Suboj P, Srinivas P, Nair AS,
Chandramohan K and Gopala S: Insidious role of nitric oxide in
migration/invasion of colon cancer cells by upregulating MMP-2/9
via activation of cGMP-PKG-ERK signaling pathways. Clin Exp
Metastasis. 29:471–492. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Browning DD, Kwon IK and Wang R:
cGMP-dependent protein kinases as potential targets for colon
cancer prevention and treatment. Future Med Chem. 2:65–80. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Riquelme I, Tapia O, Espinoza JA, Leal P,
Buchegger K, Sandoval A, Bizama C, Araya JC, Peek RM and Roa JC:
The Gene Expression Status of the PI3K/AKT/mTOR pathway in gastric
cancer tissues and cell lines. Pathol Oncol Res. 22:797–805. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guo H, German P, Bai S, Barnes S, Guo W,
Qi X, Lou H, Liang J, Jonasch E, Mills GB and Ding Z: The PI3K/AKT
pathway and renal cell carcinoma. J Genet Genomics. 42:343–353.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu Y, Yuan M, Su W, Zhu M, Yao X, Wang Y,
Qian H, Jiang L, Tao Y, Wu M, et al: The constitutively active PKG
II mutant effectively inhibits gastric cancer development via a
blockade of EGF/EGFR-associated signalling cascades. Ther Adv Med
Oncol. 10:17588340177516352018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chauvin TR, Herndon MK and Nilson JH:
Cold-shock-domain protein A (CSDA) contributes
posttranscriptionally to gonadotropin-releasing hormone-regulated
expression of Egr1 and indirectly to Lhb. Biol Reprod. 86:532012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim ES, Jeong CS and Moon A: Genipin, a
constituent of Gardenia jasminoides Ellis, induces apoptosis and
inhibits invasion in MDA-MB-231 breast cancer cells. Oncol Rep.
27:567–572. 2012.PubMed/NCBI
|
|
33
|
Wang R, MoYung KC, Zhao YJ and Poon K: A
mechanism for the temporal potentiation of genipin to the
cytotoxicity of cisplatin in colon cancer cells. Int J Med Sci.
13:507–516. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Santarpia L, Lippman SM and El-Naggar AK:
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.
Expert Opin Ther Targets. 16:103–119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hu L, Wu H, Wan X, Liu L, He Y, Zhu L, Liu
S, Yao H and Zhu Z: MicroRNA-585 suppresses tumor proliferation and
migration in gastric cancer by directly targeting MAPK1. Biochem
Biophys Res Commun. 499:52–58. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li C, Sun Z, Gui S, Liu F and Zhang Y:
Effects of fulvestrant, an estrogen receptor antagonist, on MMQ
cells and its mechanism. Neuro Endocrinol Lett. 30:268–274.
2009.PubMed/NCBI
|
|
37
|
Tu WB, Helander S, Pilstål R, Hickman KA,
Lourenco C, Jurisica I, Raught B, Wallner B, Sunnerhagen M and Penn
LZ: Myc and its interactors take shape. Biochim Biophys Acta.
1849:469–483. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim EY, Kim A, Kim SK and Chang YS: MYC
expression correlates with PD-L1 expression in non-small cell lung
cancer. Lung Cancer. 110:63–67. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li S, Lin P, Young KH, Kanagal-Shamanna R,
Yin CC and Medeiros LJ: MYC/Bcl2 double-hit high-grade B-cell
lymphoma. Adv Anat Pathol. 20:315–326. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang J, Yao YH, Li BG, Yang Q, Zhang PY
and Wang HT: Prognostic value of pretreatment serum lactate
dehydrogenase level in patients with solid tumors: A systematic
review and meta-analysis. Sci Rep. 5:98002015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jagani H, Kasinathan N, Meka SR and
Josyula VR: Antiapoptotic Bcl-2 protein as a potential target for
cancer therapy: A mini review. Artif Cells Nanomed Biotechnol.
44:1212–1221. 2016.PubMed/NCBI
|
|
42
|
Okubo S, Kurebayashi J, Otsuki T, Yamamoto
Y, Tanaka K and Sonoo H: Additive antitumour effect of the
epidermal growth factor receptor tyrosine kinase inhibitor
gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant
(Faslodex, ICI 182,780) in breast cancer cells. Br J Cancer.
90:236–244. 2014. View Article : Google Scholar
|
|
43
|
Geng X, Ma L, Li Z, Li Z, Li J, Li M, Wang
Q, Chen Z and Sun Q: Bromocriptine induces autophagy-dependent cell
death in pituitary adenomas. World Neurosurg. 100:407–416. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Toutenhoofd SL, Foletti D, Wicki R, Rhyner
JA, Garcia F, Tolon R and Strehler EE: Characterization of the
human CALM2 calmodulin gene and comparison of the transcriptional
activity of CALM1, CALM2 and CALM3. Cell Calcium. 23:232–238. 1998.
View Article : Google Scholar
|
|
45
|
Berchtold MW and Villalobo A: The many
faces of calmodulin in cell proliferation, programmed cell death,
autophagy, and cancer. Biochim Biophys Acta. 1843:398–435. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hughes A, Oxford AE, Tawara K, Jorcyk CL
and Oxford JT: Endoplasmic reticulum stress and unfolded protein
response in cartilage pathophysiology; contributing factors to
apoptosis and osteoarthritis. Int J Mol Sci. 18(pii): E6652017.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tang MK and Wong AS: Exosomes: Emerging
biomarkers and targets for ovarian cancer. Cancer Lett. 367:26–33.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Siegel JM: The neurotransmitters of sleep.
J Clin Psychiatry. 65 (Suppl 16):S4–S7. 2004.
|
|
49
|
Tyson JA and Anderson SA: GABAergic
interneuron transplants to study development and treat disease.
Trends Neurosci. 37:169–177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Southwell DG, Nicholas CR, Basbaum AI,
Stryker MP, Kriegstein AR, Rubenstein JL and Alvarez-Buylla A:
Interneurons from embryonic development to cell-based therapy.
Science. 344:12406222014. View Article : Google Scholar : PubMed/NCBI
|
